Chronic News and Research

RSS

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

Vertex Pharmaceuticals Incorporated today announced that 75% of people chronically infected with genotype 1 hepatitis C virus (HCV) who had not previously been treated achieved a sustained viral response (SVR or viral cure) after receiving a 12-week telaprevir-based combination regimen, followed by treatment with pegylated-interferon and ribavirin alone, in the Phase 3 ADVANCE trial.

26 May 2010

New approach to prevention and management of Alzheimer's disease

With the aging of nearly 80 million baby boomers, Alzheimer's disease is an impending epidemic that requires a new approach to prevention as well as management of the disease, according to a UC Santa Barbara professor who has co-authored a new book on the topic.

26 May 2010

Researchers examine association between use of antibiotics and outcomes among patients with COPD

Among patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease, those who received antibiotics in the first 2 hospital days had improved outcomes, such as a lower likelihood of mechanical ventilation and fewer readmissions, compared to patients who received antibiotics later or not at all, according to a study in the May 26 issue of JAMA.

26 May 2010

Kidney Health Week, experts criticise government inaction

Kidney Health Week is being observed at Broken Hill Hospital this week by the Broken Hill Health Service. As a part of this the residents will receive complete kidney check ups including blood pressure and blood sugar and advice regarding kidney health.

26 May 2010

Genzyme's suit stays final FDA approval of Watson's generic Renvela ANDA

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market sevelamer carbonate 800mg tablets. Watson's sevelamer carbonate tablet is the generic version of Genzyme's Renvela®. Renvela ® is a phosphate binder indicated for the control of serum phosphorus in patients with chronic kidney disease who are on dialysis.

26 May 2010

Federal law to expand coverage to kids is off to slow start

USA Today: "A federal law that President Obama signed early last year to expand health insurance to 4 million more low-income children has gotten off to a slow start because of budget problems in the states. The law makes more than $10 billion in federal aid available each year through 2013 but requires state funds as well."

25 May 2010

Verisk Health, Carena enter agreement to improve healthcare outcomes and reduce medical costs

Verisk Health, Inc., and Carena, Inc. announced today that they have signed an agreement to join forces to improve healthcare outcomes and reduce medical costs. Verisk Health is a global leader in identifying, analyzing, and predicting healthcare risk. Carena, Inc. provides consumers with 24/7 medical care and education through its network of board-certified physicians and advanced registered nurse practitioners.

25 May 2010

Rockwell Medical's SFP Phase IIb data accepted for presentation at XLVII ERA-EDTA Congress

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that Phase IIb data for its lead drug candidate Soluble Ferric Pyrophosphate (SFP) have been accepted for presentation at the XLVII European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress, organized in collaboration with the Deutsche Gesellschaft fur Nephrologie (DGfN) in Munich, Germany, June 25-28, 2010.

25 May 2010

Medtronic fiscal year 2010 revenue up 8% to $15.817 billion

Medtronic, Inc. today announced financial results for its fourth quarter and fiscal year ended April 30, 2010.

25 May 2010

CoDa Therapeutics reports positive results from Phase 2 study of NEXAGON for chronic venous leg ulcers

CoDa Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for wound care and tissue repair, today announced positive results from its Phase 2 NOVEL Study of NEXAGON® in patients with chronic venous leg ulcers. NEXAGON® is a topically applied, novel therapeutic candidate, with the potential to revolutionize the wound healing treatment paradigm by leveraging a new mechanism and target involved in the healing process.

25 May 2010

FDA grants priority review for Alkermes' VIVITROL sNDA for opioid dependence

Alkermes, Inc. today announced that the supplemental New Drug Application (sNDA) for VIVITROL® (naltrexone for extended-release injectable suspension) for opioid dependence has been designated a priority review by the U.S. Food and Drug Administration (FDA).

25 May 2010

Cytochroma reports positive Phase 1/2 results for CTAP101 Capsules in non-dialysis CKD patients

Cytochroma today announced positive Phase 1/2 results for CTAP101 Capsules, a product being developed to treat secondary hyperparathyroidism (SHPT) associated with vitamin D insufficiency in non-dialysis chronic kidney disease (CKD) patients. The study demonstrated that a single dose of CTAP101 Capsules was safe, effective and well tolerated.

25 May 2010

BIO praises Obama Administration’s dissemination of Therapeutic Discovery Project Program

The Biotechnology Industry Organization (BIO) praised the Obama Administration for its new guidance, released today, that will lead to many small biotechnology companies receiving needed funding to support critical on-going research and development programs. The guidance document initiates the Therapeutic Discovery Project Program (TDPP), which was created by the Patient Protection and Affordable Care Act signed into law by President Obama on March 23.

25 May 2010

Yissum introduces Dralgo platform to accelerate discovery of promising drug candidates

Drug discovery and development is a highly risky process, with only one in 10,000 initial candidate compounds reaching the market. When taking into account the aborted candidates, the cost of developing one successful drug may even reach $1 billion, and the development process may take as long as 15-20 years.

25 May 2010

Hawaii Pacific Health, Saint Barnabas Health Care System and XCelience achieve CEO Cancer Gold Standard

Hawaii Pacific Health, Saint Barnabas Health Care System N.J., and XCelience LLC, have received CEO Cancer Gold Standard™ accreditation, recognizing the commitment of these organizations to reducing the risk of cancer for employees and their families by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment.

25 May 2010

Researchers develop new device that can change current landscape of chronic wound management

Complex wounds affect more patients in the United States than heart attack and stroke combined, and five to seven million Americans with complex wounds account for over $20 billion in healthcare expenditures. About 150,000 amputations a year result from complex wounds, while about 80,000 are attributed to diabetes and peripheral arterial disease.

25 May 2010

Researchers determine critical role of bone marrow cells in fighting respiratory viruses

Researchers at Mount Sinai School of Medicine for the first time have determined that bone marrow cells play a critical role in fighting respiratory viruses, making the bone marrow a potential therapeutic target, especially in people with compromised immune systems. They have found that during infections of the respiratory tract, cells produced by the bone marrow are instructed by proteins to migrate to the lungs to help fight infection. The data are published in the current issue of Cell Host & Microbe.

25 May 2010

Anti-aging supplements may prevent decline in physical function: Researchers

Anti-aging supplements made up of mixtures might be better than single compounds at preventing decline in physical function, according to researchers at the University of Florida's Institute on Aging. In addition, it appears that such so-called neutraceuticals should be taken before very old age for benefits such as improvement in physical function.

25 May 2010

Researchers examine relationship between visiting primary care physician and effect blood pressure

Frequent doctor visits helped diabetes patients lower their high blood pressure to normal quicker, according to a large study reported in Hypertension: Journal of the American Heart Association.

25 May 2010

Round-up: Mississippi struggles with mental health services funding cuts; A drug discount bill advances in Mass.

"Lawmakers earlier this year vigorously fought Gov. Haley Barbour's proposal to close four state mental health hospitals and six crisis centers as a budget-saving measure. Now, nonprofit-run centers that offer front-line services for the mentally ill in some of the poorest communities across Mississippi could face closure."

25 May 2010

Chronic News and Research

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

New approach to prevention and management of Alzheimer's disease

Researchers examine association between use of antibiotics and outcomes among patients with COPD

Kidney Health Week, experts criticise government inaction

Genzyme's suit stays final FDA approval of Watson's generic Renvela ANDA

Federal law to expand coverage to kids is off to slow start

Verisk Health, Carena enter agreement to improve healthcare outcomes and reduce medical costs

Rockwell Medical's SFP Phase IIb data accepted for presentation at XLVII ERA-EDTA Congress

Medtronic fiscal year 2010 revenue up 8% to $15.817 billion

CoDa Therapeutics reports positive results from Phase 2 study of NEXAGON for chronic venous leg ulcers

FDA grants priority review for Alkermes' VIVITROL sNDA for opioid dependence

Cytochroma reports positive Phase 1/2 results for CTAP101 Capsules in non-dialysis CKD patients

BIO praises Obama Administration’s dissemination of Therapeutic Discovery Project Program

Yissum introduces Dralgo platform to accelerate discovery of promising drug candidates

Hawaii Pacific Health, Saint Barnabas Health Care System and XCelience achieve CEO Cancer Gold Standard

Researchers develop new device that can change current landscape of chronic wound management

Researchers determine critical role of bone marrow cells in fighting respiratory viruses

Anti-aging supplements may prevent decline in physical function: Researchers

Researchers examine relationship between visiting primary care physician and effect blood pressure

Round-up: Mississippi struggles with mental health services funding cuts; A drug discount bill advances in Mass.

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News